A plant inspection backlog caused by COVID-19 restrictions threatens innovation and public health. Now pressured to step up on-site inspections, will FDA embrace new methods?
Pressure is mounting on FDA to step up the pace of on-site inspections that were postponed due to COVID-19 safety issues and restrictions. An open question is whether the agency will use new remote auditing technologies to improve its ability to inspect facilities during the COVID-19 pandemic.
Read this article in BioPharm International's Regulatory Sourcebook March 2021 eBook.
BioPharm International
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 4–5
When referring to this article, please cite it as: A. Shanley, "Can FDA Reinvent Inspections, BioPharm International Regulatory Sourcebook eBook (March 2021).
EXO Biologics and ExoXpert Reach Two Critical Milestones that Advance Exosomes
December 3rd 2024EXO Biologics and its subsidiary, ExoXpert, have received GMP certification of a European exosomes manufacturing facility and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.